Red Light Holland Announces Filament Health's PEX010 Drug Candidate, the Standardized and Patented Natural Psilocybin Trusted Across 80+ Studies Globally, Selected by UCSF for Study Probing Preclinical Alzheimer's Markers
Red Light Holland announced that its subsidiary Filament Health will supply its patented psilocybin drug candidate, PEX010, to the University of California, San Francisco (UCSF). The UCSF study is a double-blind, randomized trial investigating the safety and mechanisms of psychedelics in healthy older adults, specifically looking at neuroinflammatory markers and preclinical Alzheimer's disease pathology.
Key figures
- Drug Name
- PEX010
- Patent families
- 15
- Patents acquired
- 76
- Studies worldwide
- 80+
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.